NCI researchers debuted a new deep learning model that could help you decipher the cancer tumor’s microenvironment. The model holds a lot of promise for predicting which patients are most likely to benefit from checkpoint inhibitors.
An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in…
Childhood cancer survivors in Europe exhibited higher risk for suicidal ideation than the general population, according to results of a systematic review and meta-analysis.This finding…
Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction…
Journal of Neuro-Oncology – The resolution of peritumoral brain edema (PTBE) following surgery for intracranial meningioma (IM) is poorly understood. We hypothesized that PTBE represents…
ASTRO’s weekly member newsletter for the week of March 17: ROCR Act reintroduced, Don’t miss 2025 Refresher, Leadership Pathway Program Awardees
Resources for investigators to find and make publicly available genomic summary results (GSR) data from cancer research studies.
Panelists discuss how the NCCN guidelines for risk stratification in HR+/HER2- early-stage breast cancer inform clinical decision-making, with an emphasis on biomarker testing, the use…
Early automated follow-up of cancer patients can help pharmacists more efficiently manage side effects of oral oncolytic medications, according to data presented at the ASHP…
The FDA has granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced…
Kelly E. McCann, MD, discusses mentorship in oncology and the importance of guiding patients with breast cancer through their treatment journey.
